RxDoctor Payments Data

Laura Grant, NP

Nurse Practitioner · Saint Charles, MONPI 1194240986

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $30,250 of the $34,491 with a category attached, or 87.7%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 95.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $11,404 and has fallen 56.6% since, to $4,950 in 2025. Among nurse practitioner clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,491in general payments, 2019–2025

Across 128 payments — averaging $269.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$33K
  • Abiomed$292
  • AstraZeneca$289
  • Pfizer$250
  • Edwards Lifesciences$248
  • Boehringer Ingelheim$113
  • plus $227 from 5 others

What the payments were for

  • Speaking & faculty fees$30,25088%
  • Travel & lodging$1420%
  • Food & beverage$4,09812%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,491 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$19,541
Medicare patients
161
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$52,333
BrilintaTicagrelor63$33,848
EntrestoSacubitril/Valsartan37$22,297
JardianceEmpagliflozin21$12,494
FarxigaDapagliflozin Propanediol12$9,020
ClopidogrelClopidogrel Bisulfate238$1,915
Prasugrel Hcl17$1,597
Metoprolol Succinate166$880
Ranolazine ErRanolazine17$629
Midodrine Hcl11$522
Rosuvastatin Calcium75$493
Amiodarone Hcl60$414
Atorvastatin Calcium56$325
Mupirocin51$293
Furosemide108$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$250$52,33376 claims
AstraZenecaBrilinta, Farxiga$289$42,86875 claims
NovartisEntresto$35$22,29737 claims
Boehringer IngelheimJardiance$113$12,49421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Charles

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →